Role of amphotericin B upon enhancement of protective immunity elicited by oral administration with liposome-encapsulated-Japanese encephalitis virus nonstructural protein 1 (NS1) in mice

Microbial Pathogenesis

Volumn 49, Issue 3, 2010, Pages 67-74

  Lin, Tsung Shun ^a   Chuang, Chuan Chang ^a   Hsu, Hui Ling ^a   Liu, Yu Tien ^a   Lin, Wen Po ^a   Liang, Chung Chih ^a   Liu, Wen Tssann ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Amphotericin B; Cytokine; Liposome; NF B; NS1

Indexed keywords

AMPHOTERICIN B; CHOLESTEROL; CYTOKINE; DISTEAROYLPHOSPHATIDYLCHOLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOSOME; NONSTRUCTURAL PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGICAL ADJUVANT; JAPANESE ENCEPHALITIS VACCINE; NS1 PROTEIN, FLAVIVIRUS; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CELL NUCLEUS; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOPLASM; DRUG POTENTIATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; LIPOSOMAL DELIVERY; LYMPHOCYTE; MACROPHAGE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PEYER PATCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; SINGLE DRUG DOSE; VACCINATION; VIRUS INFECTION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DISEASE MODEL; ENCEPHALITIS, JAPANESE; FEMALE; IMMUNOLOGY; METABOLISM; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS); SURVIVAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIBODIES, VIRAL; CELL NUCLEUS; CYTOKINES; CYTOPLASM; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; IMMUNOGLOBULIN G; JAPANESE ENCEPHALITIS VACCINES; LIPOSOMES; LYMPHOCYTES; MACROPHAGES; MICE; MICE, INBRED BALB C; NF-KAPPA B; PEYER'S PATCHES; SURVIVAL ANALYSIS; VIRAL NONSTRUCTURAL PROTEINS;

JAPANESE ENCEPHALITIS VIRUS; MURINAE; MUS;

EID: 77954660971     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2010.04.002     Document Type: Article

References (41)

1. Meyer R.D. Current role of therapy with amphotericin B. Clin Infect Dis 1992, 14:154-160.
2. Odds F.C., Brown A.J., Gow N.A. Antifungal agents: mechanisms of action. Trends Microbiol 2003, 11:272-279.
3. Terrell C.L., Hughes C.E. Antifungal agents used for deep-seated mycotic infections. Mayo Clin Proc 1992, 67:69-91.
4. Meyer E., Schwab F., Gastmeier P., Heininger A. Antifungal use in intensive care units. J Antimicrob Chemother 2007, 60:619-624.
5. Davidson R.N., Martino L., Gradoni L., Giacchino R., Gaeta G.B., Pempinello R., et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996, 22:938-943.
6. Sawaya B.P., Briggs J.P., Schnermann J. Amphotericin B nepherotoxicity: the adverse consequence of altered membrane properties. J Am Soc Nephrol 1995, 6:154-164.
7. Sterling T.R., Merz W.G. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist Updat 1998, 1:161-165.
8. Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother 2002, 4:7-10.
9. Tokuda Y., Tsuji M., Yamazaki M., Kimura S., Abe S., Yamaguchi H. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob Agents Chemother 1993, 37:2228-2230.
10. Shirley F.S., Little J.R. Immunopotentiating effects of amphotericin B II. Enhanced in vitro proliferative responses of murine lymphocytes. J Immunol 1979, 123:2883-2889.
11. Rogers P.D., Stiles J.K. Amphotericin B induces expression of genes encoding chemokines and cell adhesion molecules in the human cell line THP. J Infect Dis 2000, 182:1280-1283.
12. Sau K., Mambula S.S., Latz E., Henneke P., Golenbock D.T., Levitz S.M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CCD14-dependent mechanism. J Biol Chem 2003, 278:37561-37568.
13. Razonable R.R., Henault M., Lee L.N., Laethem C., Johnston P.A., Watson H.L., et al. Secretion of pro-inflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of Toll-like receptors 1 and 2. J Antimicrob Chemother 2005, 49:1617-1621.
14. Matsuo K., Hotokezaka H., Ohara N., Fujimura Y., Yoshimura A., Okada Y., et al. Analysis of amphotericin B-induced cell signaling with chemical inhibitors of signaling molecules. Microbiol Immunol 2006, 50:337-347.
15. Monath T.P., Heinz F.X. Flaviviruses. Fields virology 1996, 961-1034. Lippincott-Raven Publishers, Philadelphia, Pa. 3rd ed. B.N. Field, D.M. Knipe, P.M. Howley (Eds.).
16. World Health Organization Japanese encephalitis vaccines. Weekly Epidemiological Rec 1998, 73:337-344.
17. Tsai T.F. New initiates for the control of Japanese encephalitis by vaccination: minute of the WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000, 18:1-25.
18. Eckels K.H., Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003, 61:395-418.
19. Monath T.P. Japanese encephalitis vaccines: current vaccines and future prospects. Curr Top Microbiol Immunol 2002, 267:105-138.
20. Chambers T.J., Hahn C.S., Galler R., Rice C.M. Flavivirus genome organization, expression and replication. Annu Rev Microbiol 1990, 44:649-688.
21. Lin Y.L., Chen L.K., Liao C.L. DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicited protective immunity in mice. J Virol 1998, 72:191-200.
22. Konishi E., Ajiro N., Nukuma C., Mason P.W., Kurane I. Comparison of protective efficacies of plasmid DNA encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 2003, 21:3675-3683.
23. Lasic D.D. Novel application of liposomes. Trends Biotechnol 1998, 16:300-321.
24. Alpar H.O., Brown J.C., Brown M.R. Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int J Pharm 1992, 88:335-344.
25. Clarke C.J., Stokes C.R. The intestinal and serum humoral immune response of mice to orally administered antigens in liposomes: II. The response to liposome-entrapped bacterial proteins. Vet Immunol Immunopathol 1992, 32:139-148.
26. Phillips N.C., Gagne L., Ivanoff N., Riveau G. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 1996, 14:898-904.
27. Zhou F., Neutra M.R. Antigen delivery to mucosa-associated lymphoid tissue using liposomes as a carrier. Biosci Rep 2002, 22:355-369.
28. Han M.S., Watarai K., Kobayashi T., Yasuda H. Application of liposomes for development of oral vaccines: study of in vivo stability of liposomes and antibody response to antigen associated with liposomes after oral immunization. J Vet Med Sci 1997, 59:1109-1114.
29. MacDonald R.C., MacDonad R.I., Menaco B.M., Takeshita K., Subbarao N.K., Hu L. Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta 1991, 30:297-303.
30. Vonk A.G., Netea M.G., Dencker N.E., Verschueren I.C., van der Meer J.W., Kullberg B.J. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J Antimicrob Chemother 1998, 42:469-474.
31. Xu G., Xu X., Li Z., He Q., Wu B., Sun S., et al. Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine 2004, 22:1846-1853.
32. Eldride H., Hammond C.J., Meulbroek J.A., Staas J.K., Guilley R.M., Tice T.R. Controlled vaccine release in the gut-associated lymphoid tissue. I. Orally administered biodegradable microsphere target the Peyer's patch. J Control Release 1990, 11:205-214.
33. Liu W.T., Lin W.T., Tsai C.C., Chuang C.C., Liao C.L., Lin H.C., et al. Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge. Vaccine 2006, 26:5852-5861.
34. Shirley F.S., Little J.R. Immunopotentiating effects of amphotericin B I. Enhanced contact sensitivity in mice. J Immunol 1979, 123:2878-2882.
35. Arning M., Kliche K.O., Sonderhoff A.H., Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 1995, 38:459-465.
36. Nakajima R., Brubaker R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 1993, 61:22-31.
37. Winter P.M., Dung N.M., Loan H.T., Kneen R., Wills B., Thu L.T., et al. Porinflammatory cytokines and chemokines in humans with Japanese encephalitis. J Infect Dis 2004, 190:1618-1626.
38. Binder G.K., Griffin D.E. Immune-mediated clearance of virus from central nervous system. Microbes Infect 2003, 5:439-448.
39. Minato S., Iwanaga K., Kakei M., Yamashita S., Oku N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release 2003, 89:189-197.
40. Chen L.K., Lin Y.L., Liao C.L., Lin C.G., Huang Y.L., Yeh C.T., et al. Generation and characterization of organtropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 1996, 223:79-88.
41. Konishi E., Shoda M., Ajiro N., Kondo T. Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infection in vaccinated horses. J Clin Microbiol 2004, 42:5087-5093.